Editas Medicine Inc - Company Profile

Powered by

All the data and insights you need on Editas Medicine Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Editas Medicine Inc Strategy Report

  • Understand Editas Medicine Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Editas Medicine Inc: Overview

Select Item

Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, BlueRock Therapeutics, Bayer AG, The Broad Institute Inc, Massachusetts Institute of Technology, Harvard Institute, The Rockefeller University, Celgene Corp and Bristol Myers Squibb to discover and develop its pipeline products. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Editas Medicine Inc and make more informed decisions for your business Gain a 360-degree view of Editas Medicine Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 11 Hurley St, Cambridge, Massachusetts, 02141-2110
Website www.editasmedicine.com
Telephone 1 617 4019000
No of Employees 226
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange EDIT (NASD)
Revenue (2022) $19.7M -22.8% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -14.5% (2022 vs 2021)
Market Cap* $866.6M
Net Profit Margin (2022) XYZ -48.4% (2022 vs 2021)
* As of and is in US$
View Editas Medicine Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Editas Medicine Inc premium industry data and analytics

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Editas Medicine Inc’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of Editas Medicine Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate Editas Medicine Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Clinical Trials

Determine Editas Medicine Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
In Vivo Gene-Editing Medicines
EDIT-101- Leber Congenital Amaurosis
XYZ
XYZ
XYZ
Understand Editas Medicine Inc portfolio and identify potential areas for collaboration Understand Editas Medicine Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In October, the company announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to EDIT-301 to treat patients with severe sickle cell disease (SCD).
2023 Regulatory Approval In April, the company announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to EDIT-301.
2023 Contracts/Agreements In January, the company and Shoreline Biosciences signed an agreement for Shoreline to acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Editas Medicine Inc Vertex Pharmaceuticals Inc Sarepta Therapeutics Inc Poseida Therapeutics Inc RegenxBio Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Cambridge Boston Cambridge San Diego Rockville
State/Province Massachusetts Massachusetts Massachusetts California Maryland
No. of Employees 226 4,800 1,162 327 401
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Emma Reeve Chairman Executive Board 2023 -
Gilmore O’Neill Chief Executive Officer; President; Director Executive Board 2022 -
Erick J. Lucera Executive Vice President; Chief Financial Officer Senior Management 2023 -
Bruce E. Eaton Chief Business Officer; Executive Vice President; Chief Technology Officer Senior Management 2021 69
Linea Aspesi Chief People Officer; Executive Vice President Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Editas Medicine Inc key executives to enhance your sales strategy Gain insight into Editas Medicine Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward